Evidence map›Paper›PMID 39280654›Full record

ArticleTranslational andrology and urology2024

Comprehensive analysis of

Yuxiang Zhang, Qian Sun, Wei Meng, Lingling Xie, Ningning Li, Jiayi Zhang, Tong Zhang, Yangbo Guan, Limin Ma

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational andrology and urology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yuxiang Zhang *Department of Urology, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, China.
Qian Sun *Department of Respiratory Medicine, The First People's Hospital of Yancheng, Yancheng, China.
Wei Meng *Department of Urology, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, China.
Lingling XieDepartment of Laboratory Medicine, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, China.
Ningning LiXinglin College, Nantong University, Nantong, China.
Jiayi ZhangXinglin College, Nantong University, Nantong, China.
Tong ZhangXinglin College, Nantong University, Nantong, China.
Yangbo GuanDepartment of Urology, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, China.
Limin MaDepartment of Urology, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: In recent decades, there has been increasing evidence that Go-Ichi-Nii-San ( Methods: We used various analysis packages of R (version 3.6.3), the University of ALabama at Birmingham CANcer (UALCAN) data analysis portal, the Cancer Cell Line Encyclopedia (CCLE), the cBio Cancer Genomics Portal (cBioPortal), and the Tumor Immune Estimation Resource (TIMER) to study the gene expression, promoter methylation level, gene mutations, prognostic and diagnostic value, immune infiltration, pathway enrichment, and other aspects of the Results: The expression level of Conclusions: The analysis results showed that the differential expression of

Indexed as

bioinformatics analysisbiomarkerclear cell renal cell carcinoma (ccRCC)Go-Ichi-Nii-San subunits (GINS subunits)prognosis

Identifiers

PMID39280654
PMCPMC11399050

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.